Insight

Vanita Noronha: Neoadjuvant paclitaxel+platinum to 5-fluorouracil+platinum in esophageal/GEJ squamous cell carcinoma

Photo of Vanita Noronha/uhapo

Sep 30, 2024, 17:03

Vanita Noronha: Neoadjuvant paclitaxel+platinum to 5-fluorouracil+platinum in esophageal/GEJ squamous cell carcinoma

Vanita Noronha, Medical Oncologist at Tata Memorial Hospital, shared an article on X:

“For locally advanced Esophageal Cancer, pacli+ platiunum is non-inferior to 5FU-platinum, with less side effects and higher pCR of 26%.”

Tittle: Phase III randomized trial comparing neoadjuvant paclitaxel+platinum to 5-fluorouracil+platinum in esophageal/GEJ squamous cell carcinoma

Authors: Vanita Noronha, Vijay Maruti Patil, Nandini Menon, Amit Joshi, Minit Jalan Shah, Ajaykumar Singh, Supriya Goud, Srushti Shah, Sucheta, Kavita Nawale, Dipti Nakti, Akanksha Yadav, Shweta Jogdhankar, Rajeev Kumar, Virendra Kumar Tiwari, Devayani Niyogi, Nilendu Purandare, Amit Janu, Nivedita Chakrabarty, Abhishek Mahajan, Anil Tibdewal, Jaiprakash Agarwal, Akash Pawar, Oindrila Roy Chowdhury, Vibhor Sharma, Venkatesh Kapu, Mehak Trika, Srigadha Vivek Kumar, Manali Kolkur, Priyanka Bhagyavant, Zoya Peelay, Rutvij Khedkar, Medha Jain, Rajendra Badwe and Kumar Prabhash.

Source: Vanita Noronha/X

5FU-platinum cancer esophageal cancer Kumar Prabhash Manali Kolkur Medha Jain Nandini Menon OncoDaily Oncology Priyanka Bhagyavant Rajendra Badwe Rutvij Khedkar squamous cell carcinoma Srigadha Vivek Kumar Tata Memorial Hospital Vanita Noronha Vijay Maruti Patil Zoya Peelay

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage